A project to develop a new antitumor drug for the treatment of breast cancer has been launched at the Moscow Institute of Physics and Technology (MIPT), with a timeline set for three years. The medicine is expected to be produced in tablet form, the university’s press service reported.
In the initial stage, researchers plan to create several panels of compounds based on various chemical structures and molecular mechanisms of action, which will then be tested on cell cultures before progressing to animal trials.
Philip Maximov, an international expert in molecular oncology who previously worked at MD Anderson Cancer Center in Houston, USA, leads the project. “By the end of 2026, we expect to receive several panels of compounds that will be validated in vitro and in vivo,” he stated. Additionally, the team is collaborating with an industrial partner to assist in animal research, after which they plan to proceed to toxicological studies and potentially clinical trials.
Maximov emphasized that developing a tablet form of the drug is preferable to injections, Theas it is a painless option for patients.
The industrial partner is HimRar Group of Companies, according to TASS.
The Group offered its comprehensive services for in silico and in vitro biological activity screening, as well as synthesis and pilot research programs in pharmacokinetics, activity, and safety, back in 2023, when HimRar’s collection included over 1.6 million compounds and more than 100 ready-made focused libraries for medical and chemical projects.
